Nurix therapeutics announces presentations at the 65th american society of hematology (ash) annual meeting

San francisco, nov. 02, 2023 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that clinical data will be presented for its two btk degrader programs, nx-5948 and nx-2127, in two posters at the 65th american society of hematology annual meeting and exposition being held december 9-12, 2023, in san diego, ca. nurix will also present a trials in progress poster for its nx-1607 program.
NRIX Ratings Summary
NRIX Quant Ranking